首页> 美国卫生研究院文献>Interactive Cardiovascular and Thoracic Surgery >Is there a suitable method of anticoagulation in pregnant patients with mechanical prosthetic heart valves?
【2h】

Is there a suitable method of anticoagulation in pregnant patients with mechanical prosthetic heart valves?

机译:患有机械性人工心脏瓣膜的孕妇是否有合适的抗凝方法?

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

A best evidence topic was written according to a structured protocol in order to identify the mode of anticoagulation that has the best safety profile for both the mother and the foetus in pregnant patients with mechanical prosthetic heart valves. A total of 281 papers were identified using the reported search, of which eight represented the best evidence to answer the clinical question. The authors, date, journal, study type, population, main outcome measures and results are tabulated. The reported measures were foetal mortality, maternal mortality, congenital abnormalities and embryopathy, and maternal thromboembolic and haemorrhagic complications. The medical orthodoxy has warned of the combination of oral anticoagulation and pregnancy due to the well-documented warfarin embryopathy. Yet only one of the reported papers identified a greater incidence of foetal aberrations among warfarin use, with the highest reported rate being 6.4% and two of the assessed papers reporting no embryopathy at all. Foetal mortality with oral anticoagulation use ranged from 1.52 to 76%. All reported publications demonstrated a superior maternal outcome with warfarin use, with a range of thromboembolic events from 0 to 10% in comparison with 4 to 48% where heparin was used. Thus, it is concluded that warfarin is a more durable anticoagulant with a better maternal outcome despite it carrying a greater foetal risk. Although, in contrast to previous teaching, the risks of embryopathy are not the major drawback of oral anticoagulation. Heparin is consistently less effective, but may be preferred for the superior foetal outcome. Heparin usage during the first trimester reduces the foetal risk but is still associated with an adverse maternal outcome. While the focus for clinicians looking after pregnant women with mechanical heart valves may be to prevent maternal thromboembolic complications, the overriding concern for many women is to avoid any harm to their unborn child, even when this places their health at risk. Thus women with mechanical heart valves must be fully informed of the risks involved with different anticoagulation for an informed decision to be made.
机译:根据结构化方案编写了最佳证据主题,以鉴定在机械瓣膜人工瓣膜妊娠患者中对母亲和胎儿均具有最佳安全性的抗凝模式。使用报告的检索方法总共鉴定出281篇论文,其中八篇代表了回答临床问题的最佳证据。将作者,日期,期刊,研究类型,人口,主要结局指标和结果制成表格。报告的措施包括胎儿死亡率,孕产妇死亡率,先天性异常和胚胎病变,以及孕产妇血栓栓塞和出血并发症。医学上的正统观念已经警告华法林胚胎病,这是口服抗凝与妊娠结合的结果。然而,只有一篇报道的文献鉴定出华法林使用中胎儿畸变的发生率更高,报道率最高为6.4%,其中两篇被评估的文献完全没有胚胎病。口服抗凝治疗的胎儿死亡率为1.52%至76%。所有已报道的出版物均表明,使用华法林的母亲可获得更佳的预后,血栓栓塞事件的发生范围为0%至10%,而使用肝素的则为4%至48%。因此,可以得出结论,尽管华法林具有更大的胎儿风险,但它是一种更持久的抗凝剂,具有更好的孕产妇预后。尽管与先前的教导相反,胚胎病的风险不是口服抗凝的主要缺点。肝素的疗效一直较差,但可能会为胎儿获得更好的治疗效果。头三个月使用肝素可降低胎儿风险,但仍与不良的母亲结局有关。虽然临床医生照顾患有机械性心脏瓣膜的孕妇的重点可能是预防孕妇的血栓栓塞性并发症,但许多妇女的首要考虑是避免对未出生的孩子造成任何伤害,即使这会危害其健康。因此,必须充分告知具有机械心脏瓣膜的女性有关不同抗凝治疗的风险,以便做出明智的决定。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号